CA224-060: A randomized, open label, phase II trial of relatlimab (anti-LAG-3) and nivolumab with chemotherapy versus nivolumab with chemotherapy as first-line treatment in patients with gastric or gastroesophageal junction adenocarcinoma.

Authors

Kynan Feeney

St. John of God Hospital, Murdoch, Notre Dame University, Fremantle and Edith Cowan University, Joondalup, WA, Australia

Kynan Feeney , Ronan Kelly , Lara Rachel Lipton , Joseph Chao , Mirelis Acosta-Rivera , Dennis Earle , Ming Lei , Georgia Kollia , Niall C. Tebbutt

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2024 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Tislelizumab plus chemotherapy (chemo) versus placebo plus chemo as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup.

First Author: Hendrik-Tobias Arkenau

insert_chart_outlined

Poster

2020 Gastrointestinal Cancers Symposium

bookmark_border

Phase II study of nivolumab and relatlimab in advanced mismatch repair deficient (dMMR) cancers resistant to prior PD-(L)1 inhibition.

First Author: Katherine M. Bever

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase 2 trial of the German Gastric Group of the AIO.

First Author: Salah-Eddin Al-Batran

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

A phase II, open-label, randomized study to evaluate the efficacy and safety of GS-5745 combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.

First Author: Manish A. Shah